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Like acetylcholinesterase , butyrylcholinesterase (BChE) inactivates
the neurotransmitter acetylcholine (ACh) and is hence a viable
therapeutic target in Alzheimer’s disease, which is characterized by
a cholinergic deficit. Potent, reversible, and brain-targeted BChE
inhibitors (cymserine analogs) were developed based on binding
domain structures to help elucidate the role of this enzyme in the
central nervous system. In rats, cymserine analogs caused long-
term inhibition of brain BChE and elevated extracellular ACh levels,
without inhibitory effects on acetylcholinesterase. In rat brain
slices, selective BChE inhibition augmented long-term potentia-
tion. These compounds also improved the cognitive performance
(maze navigation) of aged rats. In cultured human SK-N-SH neu-
roblastoma cells, intra- and extracellular -amyloid precursor pro-
tein, and secreted -amyloid peptide levels were reduced without
affecting cell viability. Treatment of transgenic mice that over-
expressed human mutant amyloid precursor protein also resulted
in lower -amyloid peptide brain levels than controls. Selective,
reversible inhibition of brain BChE may represent a treatment for
Alzheimer’s disease, improving cognition and modulating neuro-
pathological markers of the disease.
anticholinesterase  long-term potentiation  dementia 
memory  neurodegeneration
Cholinergic neurons of the basal forebrain play a crucial role inbrain, with extensive cortical projections that modulate other
neurotransmitters (1). These cholinergic systems are known to be
involved in cognitive and behavioral functions that are widely
disturbed in Alzheimer’s disease (AD). In particular, AD is char-
acterized by a forebrain cholinergic neuron loss and a progressive
decline in acetylcholine (ACh) (2, 3).
Activity of ACh in the brain is terminated by the hydrolytic action
of cholinesterases (ChEs). Inhibitors of these enzymes have hence
been developed to augment the activity of surviving cholinergic
neurons in patients with AD. All ChE inhibitors (ChEIs) currently
licensed for AD inhibit acetylcholinesterase (AChE, EC 3.1.1.7)
and, to a varying extent, butyrylcholinesterase (BChE, EC 3.1.1.8),
a second ChE in brain (4). AChE and BChE have numerous
physiological functions depending on their localization and time of
expression (5).
The classical action of AChE is to catalyze the hydrolysis of ACh
within cholinergic synapses of the brain and autonomic nervous
system (6). Although BChE shares some of these functions, its role
in brain remains unclear. To define its role in brain, selective
inhibitors were designed and synthesized based on the x-ray crys-
tallographic structure of the binding sites for ACh that differentiate
BChE from AChE (7). These were assessed preclinically based on
the following facts.
In healthy human brain, AChE predominates over BChE activity
(1), but the latter likely has been previously underestimated (8).
Whereas, histochemically, AChE is localized mainly to neurons,
BChE is associated primarily with glial cells, as well as to endothelial
cells and neurons (9). An important feature distinguishing BChE
from AChE is its kinetic response to concentrations of ACh;
reflected in their Km values. BChE is less efficient in ACh hydrolysis
at low concentrations but highly efficient at high ones, at which
AChE becomes substrate inhibited (10). Hence, a possible role for
brain BChE, particularly when associated with glia, is for supportive
hydrolysis of ACh. Under conditions of high brain activity, local
synaptic ACh can reach micromolar levels that approach inhibitory
levels for AChE activity. The close spatial relationship of glial
BChE would allow synergistic BChE-mediated hydrolysis to assist
in the regulation of local ACh levels to permit the maintenance of
normal cholinergic function. The survival of AChE knockout mice
(8) with normal levels and localization of BChE (11) supports the
concept that BChE has a key role that can partly compensate for
the action of AChE.
In AD, AChE is lost early by up to 85% in specific brain regions,
whereas BChE levels (2, 12), chiefly the G1 form, rise with disease
progression. The ratio of BChE to AChE changes dramatically in
cortical regions affected by AD from 0.2 up to as much as 11 (1).
Clearly, this altered ratio in AD brain could modify the normally
supportive role of BChE in hydrolyzing excess ACh only. Selective
BChE inhibition may therefore be useful in ameliorating a cholin-
ergic deficit, which likely worsens in AD due to increased activity
of BChE.
Histochemical studies show that some cholinergic neurons con-
tain BChE instead of AChE (13). In fact, 10–15% of ChE-positive
cells in human amygdala and hippocampus are regulated by BChE
independently of AChE (14). Augmenting cholinergic function by
inhibiting these pathways may be of clinical value. Indeed, clinical
studies with the dual ChEI, rivastigmine (Exelon, Novartis), support
a role for the central inhibition of BChE in addition to AChE in AD
therapy, based on the high correlation of the former with cognitive
improvement (15).
In the AD brain, increasing levels of BChE correlate positively
with the development of hallmark cortical and neocortical amyloid-
rich neuritic plaques and neurofibrillary tangles (3, 16). The precise
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role of -amyloid peptide (A), which accumulates in neuritic
plaques, is not well understood. It is cleaved from -amyloid
precursor protein- (APP) by specific secretases, -, -, and  (17),
and A (particularly A42) appears to be toxic to neurons (18).
Therefore, reducing A synthesis is a major focus of current AD
research (4).
In light of the suggested role of BChE in central cholinergic
transmission, its altered expression in AD brain, and probable
association with the development of neuropathologic changes, we
hypothesized that high BChE activity would be detrimental in AD
and that inhibiting this enzyme would be of clinical value. To test
this hypothesis, we synthesized selective, reversible BChE inhibi-
tors, cymserine analogs (Fig. 1), and evaluated them in well-
described models to define their actions on brain ACh, learning and
cognition at synaptic and behavioral levels, as well as on neuro-
pathological markers of AD.
Materials and Methods
BChE Inhibitors. Cymserine analogs, ()-N1-phenethylnorcym-
serine (PEC) and ()-N1,N8-bisnorcymserine (BNC) were synthe-
sized (7), and their cholinesterase inhibitory activity was deter-
mined over a range of 0.3–30,000 nM against freshly prepared
human and rat (male Fischer-344 rats, Harlan Sprague–Dawley,
Indianapolis, IN) erythrocyte AChE and plasma BChE by Ellman
technique (19), as described (7). The concentrations of compounds
required to inhibit 50% enzymatic activity (IC50) were determined
in triplicate (7).
Log octanolwater partition coefficients for cymserine and
analogs were calculated for lipophilicity assessment (20).
Animals. Animals were caged in pairs at 21°C on a 12-h light–dark
cycle, with free access to food and water. All experiments complied
with National Institutes of Health guidelines and were approved by
the Institutional Animal Care and Use Committee, or complied
with European Community regulations for the care and use of
experimental animals (CEE NE86609).
Pharmacology of BChE Inhibition. Pharmacokinetic and pharmaco-
dynamic studies were performed in anesthetized (isofuorane, Ab-
bott, Chicago) male Fischer-344 rats (21–26 months old, n 3) with
femoral artery and vein catheters to administer drug and remove
blood samples, respectively. A predrug blood sample was taken to
determine resting (no inhibition) AChE and BChE activity. Cym-
serine and analogs were given at 1.0 mgkg i.v. for pharmacokinetic
studies and at 1.0 and 10 mgkg i.p. for enzyme inhibition studies.
Brain and plasma drug levels were determined by high-pressure
liquid chromatography as described for phenserine (20). Plasma,
brain, or cerebrospinal fluid (CSF) levels of ChE inhibition were
determined as described (20).
Cymserine time-dependent concentration or BChE inhibition
data were fitted by nonlinear regression analysis to a single expo-
nential equation: C  Aeat. Where C is either the cymserine
concentration (gml or gg) or percent BChE inhibition at time
t (min), A is the theoretical zero-time concentration or percent
inhibition in a central compartment, and a is the apparent first-
order elimination rate constant (min1). Half-life (T1/2) values were
then determined by the formula: T1/2  0.693a. Areas under the
concentration-time profiles were calculated by the trapezoidal rule
and used to define the brainplasma time-dependent concentration
ratio of the compound after i.v. administration.
To determine a maximum tolerated single dose, compounds
were given to male Fischer-344 rats in increasing doses (1–30 mgkg
i.p., n  3). Acute adverse effects, particularly associated with
cholinergic overdrive (e.g., tremor, salivation) were noted so that
animals in distress could be killed.
In Vivo Determination of ACh. Microdialysis. Extracellular ACh levels
were measured in the parietal cerebral cortex of male Wistar rats
(Harlan), 220–250 g weight, by microdialysis (21). Briefly, after
anesthesia, a microdialysis tube (AN 69 membrane, Hospal Dasco,
molecular mass cutoff  15 kDa) was inserted transversally into the
rat brain at the following coordinates: anteriorposterior 0.5 and
dorsoventral 2.5 mm from bregma (22). After recovery, the
membrane was perfused with Ringer’s solution at a constant flow
rate of 3 lmin. Dialysate was collected over successive 20-min
intervals into minitubes preloaded with 5 l of 0.05 mM HCl to
prevent ACh hydrolysis. Animals were given PEC 1.25 and 2.5
mgkg i.p. 80 min after microdialysis started.
Measurement of ACh. Levels of ACh in dialysates were quantified as
described (21). The detection limit for ACh was 40 fmol per
injection (40-l loop). One-way ANOVA followed by Fisher’s least
significant difference post hoc analysis was used for statistical
analysis of ACh release data.
Measurement of Brain AChE and BChE inhibition. A matched separate
series of naı̈ve male Wistar rats were administered either PEC (2.5
mgkg i.p.) or vehicle (n  4 per group) in a manner similar to
animals undergoing microdialysis. They were killed 40 min there-
after, parietal cerebral cortex was removed, and levels of AChE and
BChE activity were determined (20).
Ex Vivo Long-Term Potentiation (LTP). A well defined experimental
system for inducing LTP (23, 24) was used to investigate effects of
BChE inhibition.
Slice Preparation. Studies were performed on transverse slices of rat
brain (male Sprague–Dawley–Harlan, 10–25 days old, n  6).
Standard procedures for preparing and maintaining hippocampal
slices (350 m) in artificial CSF (ACSF) were used (25, 26). Slices
were allowed to recover for at least 1 h, transferred to a submerged
recording chamber, and continuously perfused at 2 mlmin in
media (30–32°C).
Electrophysiological Recording. ACSF for LTP experiments con-
tained 25 M picrotoxin to block GABAA-mediated activity and
optimize excitability. Stimuli (30 s; 0.033 Hz) were delivered
through fine bipolar tungsten electrodes to activate Schaffer
collateralcommissural afferents (27). The field excitatory
postsynaptic potentials (fEPSPs) were recorded in CA1 stratum
radiatum with electrodes containing ACSF (impedance of 2–4
M) using an Axopatch-1D amplifier (Axon Instruments). The
presence of BChE in the neuropil of rodent hippocampus has
been confirmed (11).
Slices with a steep input–output curve were selected for study.
Stimulation intensity was adjusted to evoke fEPSPs of 30%
maximum amplitude. The LTP-inducing stimulus consisted of a
single train of 100 stimuli at 100 Hz after 10 min of stable baseline
recording. The fEPSPs were filtered at 2 KHz, digitized at 4 KHz
on a Digidata 1322A interface (Axon Instruments) and recorded by
computer. Data were collected and analyzed on or off line by using
PCLAMP 8 software (Axon Instruments).
Drug Administration. PEC (5 mM) was added to the preparation
(n  6) to provide a final concentration of 5 M. Because PEC was
initially dissolved in ethanol and Tween 80 (final volume 0.065%
and 0.1%, respectively) to facilitate solubility in ACSF, a vehicle
Fig. 1. Chemical structure of cymserine analogs.
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control lacking PEC was used in addition to an untreated control
(n  6 each).
Maze Learning. Male Fischer-344 rats (350–500 g, aged 21–26
months) were assigned randomly to physiological saline (con-
trols, n  53) or PEC or BNC both at 0.25 and 0.5 mgkg (n 
8–10 per group). Drugs were freshly prepared daily in phys-
iologic saline (injection volume, 0.1 mlkg i.p.) and were given
twice daily (9 a.m. and 3 p.m.): day 1, injections given and rats
immediately returned to their cages; day 2, injections given 30
min before pretraining; days 3 and 4, injections given 30 min
before training.
Learning Assessment. The apparatus and procedures for one-way
active avoidance pretraining in a straight runway and subsequent
acquisition training in a 14-unit T maze have been described
(28, 29).
Statistical Analysis. Behavioral measures (errors and runtime) were
averaged across four consecutive trials and analyzed over four
separate blocks, divided equally between morning and afternoon in
the 2-day study. Data were then analyzed by using ANOVA for
group, block, and group  block factors. Post hoc group compar-
isons were made using Fisher’s least significant difference test for
all data collapsed over the 16 trials.
Neuropathological Markers in Vitro. Human neuroblastoma cells
(SK-N-SH), obtained from American Type Culture Collection
(Manassas, VA), were incubated with PEC, BNC, and cym-
serine (0.01–10 m) or without compound in 0.5% serum
media for 16 h (30). Cell viability was assessed by methyl
tetrazolium salt metabolic assay (Promega) as well as by
sensitive lactate dehydrogenase assay (30, 31). Cell samples
and culture supernatant were used to assess intracellular and
secreted protein, respectively.
APP Quantification. Conditioned media from each plate were
collected, and the cells were centrifuged (800  g, 10 min) and
lysed as described (31). Then, 15 g of protein from each sample
was mixed with Laemmli buffer, boiled for 5 min, loaded on to
a 10% Tris-Glycine gel in 1 SDS running buffer (Novex, San
Diego), and the proteins were separated at 150 V for 90 min.
Gels were transferred on to poly(vinylidene difluoride) at 25 V
for 1.5 h. Each blot was probed for 2 h with the mAb 22C11
anti-APP N-terminal antibody (Chemicon) diluted to 2.5 mgml,
which recognizes all mature forms of APP. Blots were then
placed in secondary antibody, anti-mouse or -rabbit IgG conju-
gated to horseradish peroxidase (Sigma) for 30 min. The samples
were detected by chemiluminescence and exposed to film (Am-
ersham Pharmacia). Densitometric quantification of blots was
done with a charge-coupled device camera and NIH IMAGE
(version 4.1). To verify APP quantification with mAb 22C11,
mAb 6E10 directed at residues 1–17 of A within APP was used
in a selection of samples.
A Quantification. Human A40 levels were quantified by colori-
metric ELISA (Biosource, Camarillo, CA). Briefly, a 150-l sample
of culture supernatant was added to the precoated plate with
capture antibody (specific for the N terminus of A40) and
incubated overnight at 4°C. The secondary (specific for the C
terminus of A40) and detection antibodies were added and
incubated for 3 h at room temperature. A40 levels were detected
at 450 nm against appropriate standards.
Neuropathological Markers in a Transgenic (Tg) Mouse Model. Drug
administration. Five-month-old male double-Tg mice (human APP
swePS1) that overexpress A (32) were given either PEC 3.0
mgkg i.p. or vehicle (saline) daily for 3 weeks (n  12 per
group).
A quantification. Animals were killed, and brain samples (parietal
cerebral cortex) collected and immediately frozen to 70°C. Levels
of A40 and A42 were quantified after formic acid extraction
using published methods (33).








selectivityAChE BChE AChE BChE
Cymserine 760  20 50  1 15-fold 800  25 38  7 21-fold
PEC 30,000 6  1 5,000-fold 30,000 9  2 3,300-fold
BNC 110  15 1  0.1 110-fold 150  20 1  0.5 150-fold
Fig. 2. Time-dependent brain and plasma concentrations of cymserine
(SEM) after 1 mgkg i.v. (A) and percentage inhibition of plasma BChE by
cymserine (SEM) after 10 mgkg i.p. (B) in rat. Brain cymserine levels were
significantly higher than plasma cymserine levels at all times (P 	 0.05,
Student’s t test).










Pharmacological Profile of Previously Undescribed BChE Inhibitors.
Modification of cymserine in the N1 and N8 positions provided
potent and selective inhibitors of BChE (Table 1). Lipid solubility
predicted high blood–brain barrier permeability, indicated by cal-
culated Log P values of: cymserine, 3.51; PEC, 5.72; and BNC, 1.80.
In plasma, cymserine concentration was 0.66  0.02 gml at 15
min, which declined with a T1/2 of 53.7 min. Cymserine readily
entered brain tissue, reaching 36.1  6.0 gg at 15 min and then
declined with a T1/2 of 27 min (Fig. 2A). Brain concentrations were
significantly greater than concomitant plasma ones at all times (P 	
0.05, Student’s t test). The brain to plasma concentration ratio of
cymserine was 40:1 (calculated 15–120 min after administration).
Administered at 10 mgkg i.p., cymserine achieved a peak of
65  4% inhibition of plasma BChE at 60 min, which declined with
a T1/2 of 11 h (Fig. 2B). In animals receiving a lower dose (1 mgkg),
BChE was maximally inhibited by 30  3% in plasma and 85  5%
in CSF, both at 60 min. In all cases, AChE inhibition was 	20%. No
ChE inhibition was found at 48 h.
No adverse actions of cymserine, BNC, or PEC were observed at
doses up to 30 mgkg i.p. Administration of higher doses was
limited by the aqueous solubility of the compounds.
BChE Inhibition Increases Brain ACh Levels. Microdialysis studies
showed that i.p. PEC induced dose-dependent increases in endog-
enous extracellular concentrations of ACh in parietal cortex. The
maximal effect was 40 min after 1.25 and 2.5 mgkg, with a
significant increase in ACh of 180% and 290%, respectively,
compared with preadministration levels (both P 	 0.05) (Fig. 3).
The ACh concentration remained high for the next 40 min (P 	 0.05
at 160 min with 2.5 mgkg), finally reaching control levels 2 h after
drug administration.
The degree of AChE and BChE inhibition in parietal cortex was
determined at the time of peak ACh elevation. After PEC 2.5
mgkg i.p., BChE was inhibited by 53  5% at 40 min. In contrast,
there was no inhibition of AChE in the same region, supporting the
BChE-specific activity of PEC.
BChE Inhibition Enhanced LTP in the Hippocampus. High-frequency
stimulation (HFS) induced LTP with a magnitude of 143.08 
13.3% fEPSP in untreated control preparations. In hippocampal
slices treated with vehicle alone, HFS induced LTP at a magnitude
that was not significantly different from that of untreated controls
(150  16.5% fEPSP). In the presence of PEC, LTP was signifi-
cantly enhanced, with a magnitude of 192.08  23.6% fEPSP (P 	
0.05 vs. both controls, Dunnett’s t test). Fig. 4 shows the change in
LTP with and without PEC at a concentration that achieves
selective BChE inhibition (Table 1).
BChE Inhibition Improved Cognitive Performance in Aged Rats. Over
successive blocks, rats learned to negotiate the maze with fewer
errors (Fig. 5A) and more quickly (Fig. 5B) when administered a
BChE inhibitor.
For both errors and runtime, ANOVA revealed significant main
Fig. 3. Percent changes from baseline in extracellular concentrations of ACh
(SEM) in rat parietal cortex, at steady state and after i.p. PEC. Asterisk
indicates a significant ACh elevation vs. baseline (P 	 0.05, Fisher’s least
significant difference).
Fig. 4. Extracellular fEPSPs (SEM) in CA1 stratum radiatum after induction
of LTP in rat hippocampal slices in the presence of PEC (5 M) and vehicle
control. PEC significantly enhanced LTP vs. control (P 	 0.05, Dunnett’s t test).
Fig. 5. Mean (SEM) number of errors made (P 	 0.05 for PEC 0.5, BNC 0.25,
0.5 mgkg vs. control) (A) and runtime (P 	 0.05 for all PEC and BNC doses vs.
control) (B) in BNC- and PEC-treated groups of aged rats relative to controls,
during acquisition training in the 14-unit T-maze.
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effects of both group (drugcontrol) and block, but no significant
group  block interaction, permitting all data to be collapsed over
the 16 trails. Subsequent post hoc analysis showed that animals
receiving PEC (0.5 mgkg) and BNC (0.25 or 0.5 mgkg) made
significantly fewer errors than controls (P 	 0.05) (PEC 0.25 mgkg
was no different from control). Moreover, animals receiving either
dose of BNC and PEC had significantly faster runtimes in the maze
than controls (P 	 0.05).
BChE Inhibition Reduced APP and A Levels in Vitro and in Vivo.
Administering cymserine and analogs to human neuroblastoma
cells significantly reduced levels of intracellular and secreted APP
and secreted A40 without altering cellular viability. Fig. 6 shows
the effect of PEC on these potential neuropathological markers. At
1.0 M and above, PEC significantly lowered intracellular and
secreted APP and secreted A40 levels compared to controls (P 	
0.05, Dunnett’s t test).
In Tg mice expressing human A (Fig. 7), treatment with PEC
led to a significant 54% reduction in A40 and a 47% reduction in
A42 from the concentrations seen in controls (P 	 0.05, Student’s
t test).
Discussion
In light of the suggested role of BChE in central cholinergic
transmission, its altered expression in the AD brain, and its prob-
able association with the development of neuropathologic changes,
we hypothesized that high BChE activity would be detrimental in
AD and that inhibiting this enzyme would be of clinical value.
Previously, we designed and synthesized ChEIs by matching the
three-dimensional structure of the inhibitor to ACh binding do-
mains that distinguish BChE from AChE (7). These agents showed
a high level of specificity for BChE over AChE, compared with
ChEIs commonly used in AD (34), and their pharmacologic actions
were characterized in the present study.
Although inhibition of ACh hydrolysis by ChEIs may have
desirable effects in the brain, the same actions within the autonomic
nervous system often are dose-limiting for these drugs (1). Hence,
cholinergic therapies should optimize central rather than peripheral
activity. Among current agents, the claim that greater specificity for
AChE vs. BChE would lead to fewer systemic side effects has yet
to be borne out in practice (1). More importantly, an ideal ChEI
would have high blood–brain barrier permeability and disappear
rapidly from the periphery, acting primarily in the brain. After
systemic administration in rat, cymserine analogs readily enter the
brain, in accord with their log P values, where they produce
long-lasting reversible inhibition of BChE. Acute, high doses of
cymserine up to 30 mgkg i.p. in rodents do not result in classical
cholinergic toxicity, with no evidence of tremor, increased saliva-
tion, or lacrimation as found with high doses of selective AChE
inhibitors (20). By comparison, the selective AChE inhibitor,
phenserine, would be lethal at this dose (20). Therefore, cymserine
and analogs appear to have a favorable pharmacological profile.
The functional importance of BChE was previously underesti-
mated because of its relatively low expression in the normal
mammalian brain compared with AChE (8). However, research by
Mesulam et al. (11, 35) and others (9, 10) has led to increased
interest in defining the role of this ‘‘orphan enzyme’’ within the
nervous system and evaluating its importance in coregulating local
concentrations of ACh, particularly in conditions such as AD.
Our microdialysis study assessed whether selective inhibition of
BChE alters the concentration of ACh after synaptic release. The
results clearly showed that cortical extracellular ACh levels in rat
were dose-dependently elevated after BChE inhibition. Previously,
the same microdialysis technique showed that extracellular ACh
levels in the cortex and hippocampus are 50% lower in aged vs.
young rats (21, 36). In a similar study, the unselective ChEI, tacrine,
produced marked increases in extracellular ACh levels in both
young and aged animals, linked to improved acquisition of a passive
avoidance conditioned response in the aged rats, indicating en-
hanced cognitive function (21). Similarly, metrifonate (an unselec-
tive ChEI) led to higher extracellular ACh levels and restored object
recognition in aged rats (36), suggesting that elevated ACh in this
model is of behavioral relevance.
Thus, we examined the effects of selective BChE inhibition and
associated increases in ACh on cognitive function at the molecular
and behavioral levels. LTP is widely used to assess mechanisms
affecting synaptic connectivity that underlie processes of learning
and memory. In LTP, brief periods of intense synaptic activity (as
triggered when learning a new task or produced experimentally
during acquisition of passive avoidance) can cause a marked and
long-lasting strengthening of communication between glutamater-
gic synapses, and are part of the neurochemical basis of memory
engram formation (23, 24). This effect can be replicated experi-
mentally in brain slices, because a test stimulus applied at a specific
region before HFS will produce a postsynaptic response of a certain
magnitude, whereas the same test applied after HFS will produce
a greater response. It is reasonable to postulate that changes in ACh
availability would indirectly modulate LTP, because the cholinergic
system projects widely in the brain and plays a key role in modu-
lating glutamatergic neurotransmission (1). It is well documented
that ACh is involved with hippocampal synaptic plasticity, learning,
and memory processes (37–39). Our study substantiates this finding,
because a potent inhibitor of BChE enhanced the magnitude of
Fig. 6. Concentration-dependent reductions in APP and A40 by PEC (ex-
pressed as a percent of control values  SEM, n  4), in SK-N-SH cells. All doses
of PEC significantly lowered extracellular APP, and PEC  1 M lowered
intracellular APP and extracellular A40 vs. control (P 	 0.05, Dunnett’s t test).
Fig. 7. Reductions in brain levels of A40 and A42 in Tg mice overexpressing
human A, after daily treatment with PEC or vehicle control (P 	 0.05 PEC vs.
control, Student’s t test).









LTP produced by HFS in hippocampal slice preparations compared
with controls. Therefore, these results indicate that increased
availability of ACh mediated by PEC could have the ability to
enhance learning and memory. Although LTP is a classic function
of glutamatergic synapses (reviewed by Francis, ref. 40), a recent
study suggested that cholinergic neurons may also have similar
plasticity. Colgin et al. (25) showed that endogenous activity of
cholinergic pathways in the hippocampus (probably within the field
CA3) could induce electrophysiological responses that resembled
LTP following brief periods of intense activity. Therefore, the role
of cholinergic neurons in learning and memory may involve direct
effects besides a modulatory role via glutamatergic synapses.
Our data show that, besides enhancing synaptic connectivity,
selective BChE inhibition with cymserine analogs also improves
cognitive performance of elderly rats in a 14-unit T-maze paradigm.
The favorable effect was evident at well below what might be
expected to represent a maximum tolerated dose, and the magni-
tude was similar to that of the AChE inhibitor, phenserine (29).
Studies investigating genetic variants of BChE (the K- and atypical-
variants: BChE-K and -A) that are associated with a lowered innate
ACh hydrolytic activity, suggest that links may exist between
specific polymorphisms and AD pathology, but this remains con-
troversial (41). Nevertheless, recent studies in humans support the
potential role of BChE in cognition. In patients with dementia,
BChE variants correlated with a preserved attentional perfor-
mance and a reduced rate of cognitive decline (42, 43). Also, in
Lewy body dementia, where the cholinergic deficit is considered
more profound than in AD (44), a prospectively designed study of
autopsy-confirmed cases showed a highly significant association
between lower activity of BChE in the temporal cortex and a slower
rate of cognitive decline (45).
In AD brain, increasing levels of BChE correlate positively with
the presence of amyloid-rich neuritic plaques (3, 16, 17). Despite
being characteristic of AD, the precise roles of APP and A
associated with plaques remain to be fully defined (4, 17). Recent
evidence suggests that small, soluble oligomers of A are potent
inhibitors of hippocampal LTP, which has been linked to synaptic
failure and memory loss (46, 47). In AD patients given the dual
ChEIs tacrine or rivastigmine, there was no significant increase in
the CSF levels of A42 with either agent over the 1-year study (48).
Therefore, it was worth determining the effects of the BChE
inhibitors on the synthesis and secretion of neurotoxic A. In a
human neuronal cell line, cymserine analogs reduced levels of
secreted A and APP without affecting cell viability. This action
translated in vivo, as PEC significantly lowered A levels in Tg mice
with accelerated A deposition caused by overexpression of human
APP. The mechanisms underpinning this action may involve both
cholinergic and noncholinergic actions regulating APP synthesis
and processing, as characterized with the AChE selective analog,
phenserine, which lowers the translational efficiency of APP
mRNA (30). In another study of mice overexpressing APP, there
was a positive correlation between A deposition and memory
impairment (49).
In summary, selective, reversible inhibition of BChE in the brain
by cymserine analogs may represent a treatment for AD, with
actions on learning and memory, probably mediated through
elevated ACh and lower A levels. A unique and attractive feature
of cymserine analogs is that they can selectively silence BChE
without apparent adverse cholinergic actions, although results from
ongoing formal toxicology studies are required. Indeed, a small
percentage of humans have mutations in BChE that render it
inactive, and yet lead normal lives (50). The clinical applications of
these agents would appear to hold great potential.
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